ROADMAP: Finding the best surgical and antibiotic approach for infected artificial hips and knees
Official title: The RandOmised Arthroplasty Infection worlDwide Multidomain Adaptive Platform (ROADMAP) Trial
Run by University of Newcastle, Australia · NCT06771050 · Data updated 2026-11-12
This study tests different surgical and antibiotic strategies to see which works best for adults with infected hip or knee implants.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2500 (estimated) |
| Sponsor | University of Newcastle, Australia Academic / other |
| Locations | 43 sites (Garran, Australian Capital Territory and 42 other locations) |
| Status | Recruiting |
| Started | March 24, 2025 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2029 |
| Registry record updated | July 27, 2026 |
| Trial ID | NCT06771050 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a confirmed or likely prosthetic joint infection of a large joint (hip or knee) at participating hospitals.
✕Probably not a fit
Patients with infections in joints other than the index large joints (hip/knee) or those who do not meet randomization criteria may not benefit from this platform.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
ROADMAP uses an adaptive platform design to compare multiple management strategies for prosthetic joint infections, including debridement with implant retention, antibiotic choices and durations, and revisions. It focuses on three infection stages (early, late acute, chronic) and follows patients in real-world care settings across several Australian sites. The trial collects detailed infection and treatment data into a central ROADMAP database and a regional registry to enable robust comparisons. It does not require additional tests beyond standard care, but it uses randomization within a platform to identify the most effective combinations. Outcomes are assessed at 12 months to determine the best approach for cure and recovery.
Why it matters
Potential benefit: If successful, the trial could identify more effective surgical and antibiotic strategies to cure prosthetic joint infections and reduce recurrence.
How similar studies have gone: Prior randomized trials in PJIs are few and have small samples, making this adaptive platform approach novel and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. "Confirmed" or "Likely" Prosthetic joint infection of a large joint according to European Bone and Joint Infection Society (EBJIS) criteria (2021) 2. Physically present at participating hospital at time of eligibility assessment 3. "Current" prosthetic joint infection, meaning symptoms and/or signs of the PJI are present at the time of eligibility assessment. Exclusion Criteria: Potentially eligible participants meeting any of the following criteria at the time of eligibility assessment for platform entry will be excluded from the randomised platform (but may still participate in the registry): 1. The index prosthetic joint is a shoulder, elbow, wrist or ankle. 2. Known previous participation in the randomised ROADMAP randomised platform for the index joint. 3. Known previous participation in the randomised ROADMAP platform for a joint other than the index joint within the 12 months prior to eligibility assessment 4. Treating clinician believes that death is imminent and inevitable. 5. Treatment is not with curative intent. 6. Patient is not classifiable into one of the three defined silos. 7. Patient is unlikely to be accessible for follow up over the 12 months following platform entry. 8. Treating team deems enrolment in the study is not in the best interests of the patient. To be included in any of the following Domains the participant must be eligible for the PLATFORM ( as listed above) and none of the platform-level exclusion criteria AND all of the domain-level inclusion and none of the domain-level exclusion criteria. Domain-specific eligibility criteria Each domain may have additional criteria for eligibility. Participants who fulfil the above criteria will be assessed for enrolment into all domains active at a participating site. At least 2 interventions (which may include standard of care) within a domain must be available to an eligible participant in order for that participant to enter the domain. The minimum number of interventions within a domain is two. The availability of interventions within domains will be region- and site-specific, although the default position is that all interventions within a domain will be available at all sites. Surgical Strategy Domain: Late Acute Silo inclusion criteria Patient is in the Late Acute silo, meaning all of the following 3 criteria are met: 1. Onset of symptoms is \>30 days after implantation of the index joint 2. Treating team feel that either DAIR or revision is appropriate for this patient. 3. The infected prosthesis is a primary arthroplasty. Surgical Strategy Domain: Late Acute Silo exclusion criteria <!-- --> 1. Any previous episode of native joint septic arthritis or PJI in the index joint 2. A definitive DAIR has already occurred for this episode of infection. 3. A revision has already occurred for this episode of infection 4. Loosening or instability of any component of the prosthesis 5. Predicted inadequate soft tissue coverage for wound closure 6. One or more of the causative organisms is a fungus or a "difficult to treat" bacterium. 7. Treating team deems enrolment in this domain is not in the best interests of the patient. Antibiotic Choice Domain inclusion criteria 1. The time of eligibility assessment is between 48h and 7 days following initial surgical treatment. 2. One or more of the causative organisms is a Gram-positive of interest OR the infection is culture negative. Antibiotic Choice Domain exclusion criteria <!-- --> 1. Previous hypersensitivity reaction to rifampicin 2. The patient is receiving a concomitant medication with an expected clinically significant drug interaction with rifampicin, which cannot be ceased, substituted for an alternative agent, or mitigated by dose adjustment. 3. One or more causative Gram-positive organisms of interest have in-vitro evidence of resistance to rifampicin 4. Known pregnancy or breastfeeding 5. Treating team deems enrolment in this domain is not in the best interests of the patient. Antibiotic Duration Part A Domain inclusion criteria 1. A single stage revision procedure has been performed For the purposes of this domain, the definition of a single stage revision procedure is as follows: A one-stage revision means: • Arthrotomy • Removal of all prosthetic components • Comprehensive synovectomy • Placement of "definitive" new components * could be primary or revision components • With no plans for a second stage operation Additional recommended elements (not part of definition, but considered 'ideal' elements of this procedure): * Removal of all loose cement; well-fixed cement may be retained. * Double set up (using a separate set of sterile instruments and drapes for the reimplantation) Antibiotic Duration Part A Domain exclusion criteria Patients will be excluded from this domain if, at the time of eligibility assessment, they have any of the following: <!-- --> 1. Any causative organism is a fungus or a 'difficult-to-treat' bacterium at the time of platform entry 2. Treating team deems enrolment in this domain is not in the best interests of the patient 3. The single stage revision was \>7 days ago 4. Patient no longer willing to participate in the domain Antibiotic Duration Part B Domain Eligibility assessment and allocation reveal will be performed at day 7 (+/- 3 days) from the time of the reimplantation operation - i.e. between 4 and 10 days following the reimplantation operation. The purpose of this time frame is to confirmation of negative reimplantation cultures. Antibiotic Duration Part B Domain inclusion criteria 1. A two-stage revision procedure has been performed For the purposes of this domain, the definition of two-stage revision and reimplantation procedures are defined as follows: A two-stage revision means: • Removal of all existing prosthetic components (including metal, ceramic, polyethylene) and any loose cement * Placement of a temporary prosthesis or spacer with the intention to replace this at a later time point with a permanent prosthesis * The intention to subsequently replace of the temporary spacer with a definitive prosthesis at a reimplantation operation in the future Additional recommended elements (not part of definition, but encouraged): • Use of antibiotic-loaded cement as the spacer * Use of an articulating spacer which is capable of withstanding weight-bearing A reimplantation procedure as the second stage of a two-stage revision means: • Removal of the temporary prosthesis and all associated cement * Implantation of a new prosthesis; considered the 'destination prosthesis' 2. The infected prosthesis was a primary (not revision) arthroplasty 3. At least 6 weeks of antibiotics have been received following the first stage revision, intended as treatment of the index infection 4. The reimplantation operation was done 4-10 days ago Antibiotic Duration Part B Domain exclusion criteria 1. \>6 months has passed since platform entry 2. One or more of the causative organisms is a fungus or a 'difficult-to-treat' bacterium 3. No perioperative tissue or fluid cultures were collected at the reimplantation operation 4. Perioperative cultures collected at reimplantation grow a significant organism (s) 5. Long-term antibiotic suppressive therapy is planned following the reimplantation operation 6. Treating team deems enrolment in this domain is not in the best interests of the patient 7. Patient no longer willing to participate in the domain
Where it's running
-
Blacktown Hospital
Blacktown, New South Wales, Australia Recruiting -
Campbelltown Hospital
Campbelltown, New South Wales, Australia Recruiting -
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia Recruiting -
Sutherland Hospital
Caringbah, New South Wales, Australia Recruiting -
Ramsay Research C/O Lake Macquarie Private Hospital
Gateshead, New South Wales, Australia Recruiting -
Nepean Hospital
Kingswood, New South Wales, Australia Recruiting
Show 37 more locations
-
St George
Kogarah, New South Wales, Australia Recruiting -
Liverpool Hospital
Liverpool, New South Wales, Australia Recruiting -
John Hunter Hospital
New Lambton, New South Wales, Australia Recruiting -
Prince of Wales Hospital
Randwick, New South Wales, Australia Recruiting -
Westmead Hospital
Westmead, New South Wales, Australia Recruiting -
Logan Beaudesert Hospital
Beaudesert, Queensland, Australia Recruiting -
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia Recruiting -
Mater Hospital Brisbane
South Brisbane, Queensland, Australia Recruiting -
Gold Coast University Hospital
Southport, Queensland, Australia Recruiting -
Toowoomba Hospital- Darling Downs Health
Toowoomba, Queensland, Australia Recruiting -
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia Recruiting -
Calvary Adelaide Private Hospital
Adelaide, South Australia, Australia Recruiting -
Royal Adelaide Hospital
Adelaide, South Australia, Australia Recruiting -
Flinders Medical Centre
Bedford Park, South Australia, Australia Recruiting -
The Queen Elizabeth Hospital
Woodville, South Australia, Australia Recruiting -
Eastern Health
Box Hill, Victoria, Australia Recruiting -
Northern health
Epping, Victoria, Australia Recruiting -
St Vincents
Fitzroy, Victoria, Australia Recruiting -
Western Health
Footscray, Victoria, Australia Recruiting -
The Alfred Hospital
Melbourne, Victoria, Australia Recruiting -
Latrobe Regional Hospital
Traralgon, Victoria, Australia Recruiting -
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia Recruiting -
Royal Perth Hospital
Perth, Western Australia, Australia Recruiting -
Fiona Stanley Hospital
Murdoch, Western AustraliaA, Australia Recruiting -
Te Toka Tumai (Auckland Hospital)
Grafton, Auckland, New Zealand Recruiting -
Counties Manukau (Middlemore Hospital)
Mangere East, Auckland, New Zealand Recruiting -
Waitemata (North Shore Hospital)
Takapuna, Auckland, New Zealand Recruiting -
The Canberra Hospital
Garran, Australian Capital Territory, Australia Not yet recruiting -
Bankstown- Lidcombe Hospital
Bankstown, New South Wales, Australia Not yet recruiting -
Mater Hospital Sydney ST Vincents Network
North Sydney, New South Wales, Australia Not yet recruiting -
Sunshine Coast University Hospital
Birtinya, Queensland, Australia Not yet recruiting -
Prince Charles Hospital
Chermside, Queensland, Australia Not yet recruiting -
Townsville Hospital and Health Service
Douglas, Queensland, Australia Not yet recruiting -
Redcliffe Hospital
Redcliffe, Queensland, Australia Not yet recruiting -
Launceston General Hospital
Launceston, Tasmania, Australia Not yet recruiting -
Dandenong/Monash Hospital
Dandenong, Victoria, Australia Not yet recruiting -
University Hospital Geelong
Geelong, Victoria, Australia Not yet recruiting
Study contacts
- Study coordinator: Joshua S Davis, Chief Investigator
- Email: TMG@ROADMAPtrial.com
- Phone: 61240420994
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Rifampicin-containing regimens for Cutibacterium acnes prosthetic joint infections
This trial tests whether adding rifampicin to amoxicillin or moxifloxacin can improve outcomes for adults with C. acnes prosthetic joint infections treated with one- or two-stage revisions.
-
Weight-Bearing CT for Healing of Periprosthetic Knee Fractures
This study tests weight-bearing CT scans to better assess healing after distal femur fractures around a knee implant in adults 50–90 years old who recently had revision knee surgery.
-
Comparing knee joint replacement to surgical fixation for elderly patients with distal femur fractures
This study is testing whether total knee joint replacement or surgical fixation works better for older patients with broken thigh bones near their knee to help them feel less pain and improve their daily activities.
-
Sola2 AMF Knee System added to surgery and antibiotics for knee implant infection
This trial tests whether using the Sola2 AMF Knee System with standard surgery and antibiotics helps improve knee function and quality of life in adults with a knee implant infection.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.